Status:

UNKNOWN

Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)

Lead Sponsor:

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Collaborating Sponsors:

CNR Institute of Neuroscience, Parma

University of Trieste

Conditions:

Depression, Anxiety

Healthy

Eligibility:

All Genders

18-35 years

Phase:

NA

Brief Summary

The aim of this study is to identify biologically viable targets for the treatment of major depressive disorder (MDD) and anxiety disorder (AD) with the ultimate goal of guiding physicians' therapeuti...

Detailed Description

The study is structured into two parts. In the first part the investigators will be recruiting 10 patients with MDD-AD and 10 HC, following the inclusion and exclusion criteria. Each participant will ...

Eligibility Criteria

Inclusion

  • Patients group: diagnosis of anxiety-depressive disorder based on the DSM-5 diagnostic criteria; age range between 18 and 35 years; age of onset \< 2 years; severe or moderate depression based on scores on the Hamilton Depressive Rating Scale (HAM-D; scores between 14 and 24); severe or moderate anxiety based on scores on the Hamilton Anxiety Rating Scale (HAM-A; scores between 18 and 30); patients must have both severe/moderate depression and anxiety to be included; ability and willingness to provide informed consent and adhere to study procedures.
  • Healthy controls group: age range between 18 and 35 years; ability and willingness to provide informed consent and adhere to study procedures.

Exclusion

  • Patients group: diagnosis of other Axis I and/or Axis II psychiatric conditions; substance and/or alcohol abuse and/or dependence; tumors or liver disorders; cognitive impairment.
  • Healthy controls: history of Axis I psychiatric conditions in first-degree relatives; presence of preexisting neurological conditions; substance and/or alcohol abuse and/or dependence; cognitive impairment.

Key Trial Info

Start Date :

July 15 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 14 2025

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT06167590

Start Date

July 15 2022

End Date

July 14 2025

Last Update

December 12 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

Milan, MI, Italy, 20100